Abiopharma

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001193125-26-346104 <b>Size:</b> 239 KB

Waiver: Application for Extension of Time to Hold Annual General Meeting

New Form SCHEDULE 13G - ManpowerGroup Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001140361-26-032416 <b>Size:</b> 10 KB

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001839882-26-039586 <b>Size:</b> 525 KB

New Form D - Entera Bio Ltd. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001638097-26-000003 <b>Size:</b> 24 KB

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001193125-26-346093 <b>Size:</b> 239 KB

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001839882-26-039585 <b>Size:</b> 630 KB

Sanofi 🟡 adjusted position in 0 shares (2 derivative) of Latigo Biotherapeutics, Inc. (LTGO) Transaction Date: Aug 10, 2026 | Filing ID: 345826

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Change in Interest of Chief Executive Officer, Mr Nicholas Chua

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001839882-26-039584 <b>Size:</b> 497 KB

New Form 424B2 - TORONTO DOMINION BANK <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001140361-26-032413 <b>Size:</b> 341 KB

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001918704-26-023533 <b>Size:</b> 934 KB

(10% Negative) MADRIGAL PHARMACEUTICALS, INC. (MDGL) Announces Clinical Trial Timeline Adjustment

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001839882-26-039583 <b>Size:</b> 361 KB

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001839882-26-039581 <b>Size:</b> 357 KB